Introduction: Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical.
Aim(s): Aim of this study is to evaluate efficacy and safety of high-dose SSA treatment in pts with progressive disease under standard SSA dose.
Materials and methods: Twenty-one pts (median age 56.8 yrs) with NET of different origin were retrospectively identified among 118 pts under SSA therapy. All 21 pts were treated with SSA high dose schedule treatment, after disease progression under standard dose. The median follow-up was 22.3 months (range 4-76). High dose schedule included octreotide LAR in 15 pts (73%) and lanreotide Autogel in 6 (27%).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Roberta Modica
, Ramundo V
, Marciello F
, Marotta V
, Pizza G
, Carratù A C
, De Luca di Roseto C
, Buonomano P
, Giordano C
, Trimarchi F
, Colao A
, Faggiano A
To read results and conclusion, please login ...
Further abstracts you may be interested in